
Applying Trial Eligibility to Clinical Practice
The RASolute 302 trial enrolled patients with metastatic pancreatic cancer and an Eastern Cooperative Oncology Group performance status of 0 or 1, while many patients seen in second-line practice are sicker.
The RASolute 302 trial enrolled patients with metastatic pancreatic cancer and an Eastern Cooperative Oncology Group performance status of 0 or 1, while many patients seen in second-line practice are sicker. Tanios S. Bekaii-Saab, MD, asks how these criteria translate to the clinic. Shiraj Sen, MD, PhD, compares trial participants with the patient in front of him and notes that daraxonrasib doubled overall and progression-free survival, nearly tripled response rate, and delayed deterioration of symptoms such as pain compared with chemotherapy. In that light, he considers the results applicable to most of his patients, provided laboratory parameters and other safety measures remain intact. Anne Noonan, MB BCh, PhD, calls the results spectacular and wonders whether the delay in cancer-related pain deterioration will hold in more symptomatic real-world patients; she reports early symptom improvement in her own practice. Dr. Bekaii-Saab describes patients who stop oxycodone within weeks and notes that real-world experience so far appears to corroborate the trial, although rash remains common.
Related to this article








